Among them, toclizumab targeting the IL-6R is approved for rheumatoid arthritis, juvenile idiopathic arthritis and Castleman disease while sarilumab also targeting the IL-6R is in late stage clinical trials. This evidence concerns the gene IL6R and rheumatoid arthritis.